0001193125-26-182271.txt : 20260427 0001193125-26-182271.hdr.sgml : 20260427 20260427164119 ACCESSION NUMBER: 0001193125-26-182271 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260427 FILED AS OF DATE: 20260427 DATE AS OF CHANGE: 20260427 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kelly Michael Aaron CENTRAL INDEX KEY: 0001769668 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33497 FILM NUMBER: 26901654 MAIL ADDRESS: STREET 1: C/O HOOKIPA PHARMA INC. STREET 2: 430 EAST 29TH ST. CITY: NEW YORK STATE: NY ZIP: 10016 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMICUS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001178879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 200422823 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 47 HULFISH STREET CITY: PRINCETON STATE: NJ ZIP: 08542 BUSINESS PHONE: (609) 662-2000 MAIL ADDRESS: STREET 1: 47 HULFISH STREET CITY: PRINCETON STATE: NJ ZIP: 08542 FORMER COMPANY: FORMER CONFORMED NAME: AMICUS THERAPEUTICS INC DATE OF NAME CHANGE: 20020729 4 1 ownership.xml 4 X0609 4 2026-04-27 true 0001178879 AMICUS THERAPEUTICS, INC. FOLD 0001769668 Kelly Michael Aaron false 47 HULFISH STREET PRINCETON NJ 08542 true false false false false Common Stock 2026-04-27 4 D false 72468 14.50 D 0 D Stock Options (right to buy) 10.71 2026-04-27 4 D false 36111 D 2031-06-10 Common Stock 36111 0 D Stock Options (right to buy) 8.55 2026-04-27 4 D false 45423 D 2032-06-09 Common Stock 45423 0 D Stock Options (right to buy) 12.62 2026-04-27 4 D false 30474 D 2033-06-08 Common Stock 30474 0 D Stock Options (right to buy) 10.27 2026-04-27 4 D false 42467 D 2034-06-06 Common Stock 42467 0 D Stock Options (right to buy) 5.96 2026-04-27 4 D false 74872 D 2035-06-05 Common Stock 74872 0 D The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 52,054 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger). In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. Each Option vested in full in connection with consummation of the Merger. /s/ Christian Formica, Attorney-in-Fact 2026-04-27